ALK Biomarkers
News and reporting on ALK biomarkers.
Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology
Premium
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.
Drugmakers Trying Out Decentralized Clinical Trials in Precision Oncology Though Risks Remain
Premium
The pandemic increased interest in virtual, tech-enabled enrollment strategies, but pharma wants to see if early studies succeed before jumping in.
Amid more tests, drugs, and emerging evidence, commercial insurance coverage for comprehensive genomic profiling remains inconsistent, contributing to access disparities.
LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign
Premium
LUNGevity hopes to streamline patient education messaging and reach lung cancer patients in underserved communities who miss out on comprehensive testing.
Nuvalent Raises $135M in Series B Funding
The company will use the funding to advance its lead NSCLC treatments, a ROS inhibitor and ALK inhibitor, into the clinic.